MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.90)
Consensus Price Target: $81.00 (113.27% upside)

Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016MizuhoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016WedbushReiterated RatingOutperform$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016NomuraReiterated RatingBuy$100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Brean CapitalReiterated RatingBuy$92.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2016Bank of AmericaUpgradeNeutral -> Buy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Piper JaffrayReiterated RatingOverweight$93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015BarclaysReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015Jefferies GroupReiterated RatingBuy$81.00 -> $72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/30/2015Goldman SachsBoost Price Target$126.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)
Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2016James B JonesSVPBuy500$62.50$31,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014David StackCEOSell25,000$73.94$1,848,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013David StackCEOSell15,000$55.84$837,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateHeadline
06/27/16 05:45 PMNew Market Report: Pacira Pharmaceuticals, Inc. (PCRX) - Financial and Strategic SWOT Analysis Review
06/26/16 04:53 PMMany Growth Catalysts For Pacira - Seeking Alpha
06/26/16 04:53 PMStock Performance Focus on: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph
06/23/16 09:55 AMA Biotech and a Medical Device Stock, Each With Massive Upside Potential -
06/20/16 07:21 AMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 03:13 PMPACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
06/16/16 05:59 PMPerformance watch list: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - News Oracle
06/16/16 05:59 PMEarnings Review: Ceres, Inc. (NASDAQ:CERE), Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Beacon Chronicle
06/15/16 05:42 PMRelative Strength Alert For Pacira Pharmaceuticals
06/09/16 06:06 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Fundamental Star Rating Report - CML News
06/05/16 05:45 PMPerformance Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - HNN
06/04/16 05:49 PMWill Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Surprise Analysts? - Investor Newswire
06/04/16 08:38 AMTwo Healthcare stocks to Focus: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Impax Laboratories, Inc. (NASDAQ ... - Is stories
06/02/16 06:09 PMBroker Watchlist: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Share Trading News - Broker Watchlist: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)Share Trading News01/29/2015 – Pacira Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 126 price target on the stock. The share price of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was up +1.78% during the last ...Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Quarterly EBIT At $-2.254 MillionsVanguard TribuneMichael Kors Holdings Limited (NYSE:KORS) surged 6.60%: ConocoPhillips (NYSE:COP), Pacira Pharmaceuticals, Inc ...KC Registerall 3 news articles »
06/01/16 06:16 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Quarterly EPS Estimate At $0.04 - Investor Newswire - Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Quarterly EPS Estimate At $0.04Investor NewswireFirst Call stated that Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) can touch $79.67 in coming one year. For the next quarter, the per-share earnings target is $0.04 and for ongoing fiscal at $0.33. EPS target for next year is $1.82 versus the mean EPS ...and more »
06/01/16 08:41 AMStock Review and Earnings Check on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - HNN - Stock Review and Earnings Check on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Pacira Pharmaceuticals, Inc.and more »
05/31/16 06:02 PMStocks Recent Trading Summary: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Regeneron Pharmaceuticals, Inc ... - Street Updates - Stocks Recent Trading Summary: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Regeneron Pharmaceuticals, Inc ...Street UpdatesPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) accumulated +4.26%, closing at $45.56 after floating between $43.85 and $45.70. The company has market capitalization of $1.69B. It has twelve month low of $35.78 and twelve month high of $81.28.and more »
05/31/16 01:32 PMHedge Funds Hated These Healthcare Stocks in Q1 -
05/31/16 06:42 AMPacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - PARSIPPANY, N.J., May 31, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled ...
05/30/16 10:08 PMStock Rating Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - HNN - Stock Rating Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)HNNInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.25 on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Covering ...and more »
05/28/16 08:35 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Impact Score At 100 - Stocks Daily - Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Impact Score At 100Stocks DailyAlpha One explored various online articles released on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), and it set a daily sentiment score of -0.207 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring ...and more »
05/28/16 08:35 PMKey Colony Management LLC Decreased Stake in Pacira Pharmaceuticals INC (NASDAQ:PCRX) by $5.20 Million as ... - CCH Daily News - Key Colony Management LLC Decreased Stake in Pacira Pharmaceuticals INC (NASDAQ:PCRX) by $5.20 Million as ...CCH Daily NewsAlex Lieblong decreased its stake in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 24.94% based on its latest 2016Q1 regulatory filing with the SEC. Key Colony Management Llc sold 100,025 shares as the company's stock declined 29.95% while stock ...Is it Time to Cash in Profits on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)Franklin Independentall 3 news articles »
05/27/16 12:05 AMHealthcare Stock's Latest Update : Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Pacira Pharmaceuticals ... - Is stories - Healthcare Stock's Latest Update : Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Pacira Pharmaceuticals ...Is storiesIn most recently trading session on 5/25/2016, Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) dropped -5.61% while traded on 2.19 million shares versus it's an average volume of 878.32 thousand shares. The company recorded the last trade with the price of ...and more »
05/25/16 09:16 PMAnalyst Update: Pacira Pharmaceuticals Inc, Sportsman's Warehouse Holdings Inc, and Applied Materials, Inc. - SPWH is trading at $8.91, down 9.1% -- and earlier tagged a new annual low of $8.65 -- following the company's poorly received earnings report. In addition, Goldman Sachs cut SPWH's price target to $15 from $16.50, while Baird lowered its price target to $ ...
05/23/16 12:49 PMStock Rating Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Wall Street Hints and News - Stock Rating Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.25 on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Covering ...and more »
05/22/16 07:04 PMPerformance at a Glance on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Wall Street Hints and News - Performance at a Glance on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)Wall Street Hints and NewsWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)'s stock has performed at various points in its past ...
05/20/16 09:05 PMNotable movements of Stocks: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , K2M Group Holdings, Inc. (NASDAQ ... - Street Updates - Notable movements of Stocks: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , K2M Group Holdings, Inc. (NASDAQ ...Street UpdatesIn the liquidity ratio analysis; Pacira Pharmaceuticals, Inc.'s (PCRX) debt to equity ratio was 0.47 while current ratio was 1.70. The Beta factor was 1.72. The stock's RSI amounts to 31.23. K2M Group Holdings, Inc. (NASDAQ:KTWO) after beginning at $10 ...and more »
05/20/16 10:50 AMBaron Funds Comments on Pacira Pharmaceuticals Inc. - Pacira Pharmaceuticals Inc. ( PCRX) is a specialty pharmaceutical company that sells a drug for local surgical analgesia (an anesthetic) called EXPAREL. At the end of the third quarter of -…-5, Pacira received a favorable resolution of certain FDA issues ...
05/18/16 09:27 PMMarsico Capital Management LLC Decreased Stake in Pacira Pharmaceuticals INC (NASDAQ:PCRX) by $27.94 ... - CCH Daily News - Marsico Capital Management LLC Decreased Stake in Pacira Pharmaceuticals INC (NASDAQ:PCRX) by $27.94 ...CCH Daily NewsMarsico Capital Management Llc decreased its stake in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 34% based on its latest 2016Q1 regulatory filing with the SEC. Marsico Capital Management Llc sold 537,388 shares as the company's stock declined ...Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Reports Basic Consolidated EPS At $0.0508Investor Newswireall 2 news articles »
05/17/16 07:21 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Reports Basic Consolidated EPS At $0.0508 - Investor Newswire - Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Reports Basic Consolidated EPS At $0.0508Investor NewswireFrom the parent firm, Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) diluted EPS came at $0.0449 for the year ended 2015-12-31. For the quarter ended 2015-12-31 it came at $0.0449. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) posted net basic EPS of ...Marsico Capital Management LLC Decreased Stake in Pacira Pharmaceuticals INC (NASDAQ:PCRX) by $27.94 ...CCH Daily Newsall 2 news articles »
05/16/16 08:04 PMConsensus Rating Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Wall Street Hints and News - Consensus Rating Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1.25 on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/16/16 01:07 PMNext Weeks Broker Price Targets For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Share Trading News - Next Weeks Broker Price Targets For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)Share Trading News01/29/2016 – Pacira Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Bank of America Merrill Lynch. They now have a USD 75 price target on the stock. 01/27/2016 – Pacira Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts ...and more »
05/13/16 02:34 AMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Latest Impact Score At 50 - Stocks Daily - Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Latest Impact Score At 50Stocks DailyPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has a 0.253 daily sentiment score given by Alpha One after scanning articles on various online news platform. Alpha One performs algorithm based analysis to reach stock sentiment based on content published ...and more »
05/13/16 02:34 AMPacira Pharmaceuticals Inc. (PCRX) Drops 5.14% on May 11 - Equities.com - Pacira Pharmaceuticals Inc. (PCRX) Drops 5.14% on May 11Equities.comPacira Pharmaceuticals Inc. (PCRX) was one of the Russell 2000's biggest losers for Wednesday May 11 as the stock slid 5.14% to $47.04, a loss of $-2.55 per share. Starting at an opening price of $49.27 a share, the stock traded between $46.97 and $49 ...
05/09/16 09:39 PMCheck on Analyst Ratings Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - B.O.D.Y Confidential - Check on Analyst Ratings Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1.25 on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 ...and more »
05/06/16 12:04 PMPACIRA PHARMACEUTICALS, INC. Financials -
05/06/16 03:49 AMPacira Pharmaceuticals Inc. (PCRX) Drops 5.26% on May 04 - Equities.com - Pacira Pharmaceuticals Inc. (PCRX) Drops 5.26% on May 04Equities.comPacira Pharmaceuticals Inc. (PCRX) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 5.26% to $48.83, a loss of $-2.71 per share. Starting at an opening price of $50.51 a share, the stock traded between $47.56 and $50 ...and more »
05/05/16 10:08 PMEarnings Report: Pacira Pharmaceuticals Inc (NASDAQ:PCRX) - News Oracle - Web Breaking NewsEarnings Report: Pacira Pharmaceuticals Inc (NASDAQ:PCRX)News OracleLast Trade: The Company fell -5.26% and finished at $48.83. The daily volume was measured at 1.39 million shares. The 52-week high of the share price is $81.28 and the 52-week low is $35.78. The company has a market cap of $1.85 Billion. Its latest ...Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Receives Consensus Recommendation of "Buy" from AnalystsWeb Breaking NewsPacira Pharmaceuticals, Inc. (NASDAQ:PCRX): Quick Look at Company EarningsNews Tribuneall 3 news articles »
05/05/16 01:35 AMMovers inside Traders Limelight: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Antares Pharma, Inc. (NASDAQ:ATRS) - Street Updates - Movers inside Traders Limelight: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Antares Pharma, Inc. (NASDAQ:ATRS)Street UpdatesPacira Pharmaceuticals, Inc. (PCRX) recently declared that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 10, ...and more »
05/03/16 09:20 PMPacira Pharmaceuticals Inc. (PCRX) Drops 6.65% on May 02 - Equities.com - Pacira Pharmaceuticals Inc. (PCRX) Drops 6.65% on May 02Equities.comPacira Pharmaceuticals Inc. (PCRX) was one of the Russell 2000's biggest losers for Monday May 02 as the stock slid 6.65% to $50.51, a loss of $-3.6 per share. Starting at an opening price of $54.01 a share, the stock traded between $48.51 and $55.54 ...and more »
05/03/16 09:20 PMToday's Dead Cat Bounce Stock Is Pacira Pharmaceuticals (PCRX) - TheStreet.com - The Point ReviewToday's Dead Cat Bounce Stock Is Pacira Pharmaceuticals (PCRX)TheStreet.comPacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. PCRX has a PE ratio of ...Pacira Pharmaceuticals, Inc. (PCRX) could soar to $113 in a year, analysts sayCWRU ObserverEarnings Recap: Pacira Pharmaceuticals Inc (NASDAQ:PCRX)The Point ReviewWhat Wall Street is saying about Pacira Pharmaceuticals (PCRX)ZergwatchBidness ETC -Wall Street 24 -Smarter Analystall 41 news articles »
05/03/16 11:22 AMPacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/03/16 06:50 AMPacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference - [at noodls] - PARSIPPANY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank ...
05/03/16 12:28 AMAverage Analyst Rating for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - B.O.D.Y Confidential - Average Analyst Rating for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.25 on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/03/16 12:28 AMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Sales Estimate At $1195.63 - RealistInvestor.com - Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Sales Estimate At $1195.63RealistInvestor.comZacks reported that Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) mean sales estimate for year is $1195.63 and the median is $1195.63. The targets are based on 2 calls for the quarter closed 4. The sales target range is from $938 to $1453.261, showing a ...and more »
05/03/16 12:28 AMFeatured Healthcare Stocks: Molina Healthcare, Inc. (NYSE:MOH), Pacira Pharmaceuticals Inc (NASDAQ:PCRX ... - The Point Review - Featured Healthcare Stocks: Molina Healthcare, Inc. (NYSE:MOH), Pacira Pharmaceuticals Inc (NASDAQ:PCRX ...The Point ReviewShares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) slipped -7.69% to $49.95 at 11:25 AM EDT. The stock exchanged hands of 930,036 shares recently versus average trading capacity of 703,004 shares. However recently the stock touch highest trading ...and more »
05/03/16 12:28 AMPacira Pharmaceuticals Inc (PCRX) Stock Drops on Top-Line Weakness - Bidness ETC - Bidness ETCPacira Pharmaceuticals Inc (PCRX) Stock Drops on Top-Line WeaknessBidness ETCPacira Pharmaceuticals Inc. (NASDAQ:PCRX) stock is trading down over 9% today, following the first quarter of fiscal 2016 (1QFY16) results, reported in the morning. The company managed to surpass the bottom-line expectation, despite a miss on revenues.Company Update (NASDAQ:PCRX): Pacira Pharmaceuticals Inc Reports First Quarter 2016 Financial ResultsSmarter AnalystEarnings Estimates Hot Buzz: Pacira Pharmaceuticals Inc (NASDAQ:PCRX)The Point ReviewPacira Pharmaceuticals Inc (PCRX) Releases Earnings Results, Beats Expectations By $0.06 EPSMarket DigestStreet Updates -Risers & Fallers -Web Breaking Newsall 19 news articles »
05/02/16 06:30 AMPacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results - [GlobeNewswire] - --Total Net Revenues Up 12 Percent Year-Over-Year---- EXPAREL ® Net Revenues Up 14 Percent Year-Over-Year---- Conference Call Today at 9 a.m. PARSIPPANY, N.J., May 02, 2016-- Pacira Pharmaceuticals, Inc. ...
05/02/16 06:07 AMQ1 2016 Pacira Pharmaceuticals Inc Earnings Release - Before Market Open -
04/19/16 07:15 AMPacira Pharmaceuticals Appoints Charles A. Reinhart, III, as Chief Financial Officer - [at noodls] - PARSIPPANY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Charles A. Reinhart, III, to the position of Chief Financial Officer. ...
About Pacira Pharmaceuticals

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PCRX
  • CUSIP: 69512710
Key Metrics:
  • Previous Close: $37.98
  • 50 Day Moving Average: $44.02
  • 200 Day Moving Average: $56.46
  • P/E Ratio: N/A
  • P/E Growth: 1.88
  • Market Cap: $1.41B
  • Current Quarter EPS Consensus Estimate: $0.33 EPS
Additional Links:
Pacira Pharmaceuticals (NASDAQ:PCRX) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha